RESEARCH
Tumor Surgery and Research Goes On Amid O.R. Shutdowns: A Double-Edged Sword for Patients in the COVID-19 Era .
Sarcoma care has faced significant disruption during COVID-19, as immunosuppressed cancer patients carry higher infection and mortality risks. Guidelines now stress careful triage, with priority given to high-risk primary sarcomas and the use of neoadjuvant therapy when surgery must be deferred. Virtual tumor boards and telemedicine have become essential tools to maintain multidisciplinary planning while reducing exposure. Surveillance routines have also shifted, with many follow-up visits postponed or transitioned online, raising concerns about patient reassurance but unlikely to affect long-term survival. Ongoing trials such as PARITY and SAFETY continue with modified procedures, highlighting how sarcoma teams are adapting to safeguard treatment, research, and patient wellbeing during an evolving public health crisis.
Already have an account? Log in
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
